Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
32
GTBIF Quote, Financials, Valuation and Earnings
Last price:
$7.93
Seasonality move
:
16.71%
Day range:
$7.66 - $8.08
52-week range:
$7.50 - $16.33
Dividend yield:
0%
P/E ratio:
29.37x
P/S ratio:
1.70x
P/B ratio:
1.06x
Volume:
300K
Avg. volume:
564.4K
1-year change:
-19.82%
Market cap:
$1.9B
Revenue:
$1.1B
EPS (TTM):
$0.27
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$282.9M | $0.06 | 3.41% | 650% | -- |
|
IBIO
iBio
|
-- | -$0.46 | -100% | -89.82% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$2.6M | -$0.31 | -60.77% | -99.16% | -- |
|
OGEN
Oragenics
|
-- | -- | -- | -- | -- |
|
PTN
Palatin Technologies
|
-- | -$0.51 | -100% | -25% | -- |
|
TOVX
Theriva Biologics
|
-- | -$5.25 | -- | -8.25% | $100.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$7.93 | -- | $1.9B | 29.37x | $0.00 | 0% | 1.70x |
|
IBIO
iBio
|
$2.48 | -- | $22.7M | -- | $0.00 | 0% | -- |
|
NBY
NovaBay Pharmaceuticals
|
$0.53 | -- | $2.6M | -- | $0.00 | 0% | 0.06x |
|
OGEN
Oragenics
|
$0.36 | -- | $4.3M | -- | $0.00 | 0% | 1.40x |
|
PTN
Palatin Technologies
|
$0.97 | -- | $18.9M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics
|
$1.14 | $100.00 | $3.2M | -- | $0.00 | 0% | 0.90x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
12.59% | -1.195 | 10.42% | 1.42x |
|
IBIO
iBio
|
4.41% | 6.097 | 5.41% | 3.89x |
|
NBY
NovaBay Pharmaceuticals
|
4.54% | 0.704 | 1.51% | 0.75x |
|
OGEN
Oragenics
|
-- | 5.927 | -- | -- |
|
PTN
Palatin Technologies
|
-- | -0.872 | -- | 0.99x |
|
TOVX
Theriva Biologics
|
-- | -1.027 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
GTBIF
Green Thumb Industries
|
$147.6M | $42.6M | 3.13% | 3.66% | 15.69% | $29.6M |
|
IBIO
iBio
|
-- | -$4.1M | -90.99% | -148.3% | -1820.57% | -$3.7M |
|
NBY
NovaBay Pharmaceuticals
|
$1.6M | -$1.1M | -334.47% | -461.38% | -44% | -$2.1M |
|
OGEN
Oragenics
|
-- | -$2.4M | -- | -- | -- | -$2M |
|
PTN
Palatin Technologies
|
$350K | -$7.8M | -- | -- | -2356.3% | -$7M |
|
TOVX
Theriva Biologics
|
-- | -$5M | -- | -- | -- | -$3.9M |
Green Thumb Industries vs. Competitors
-
Which has Higher Returns GTBIF or IBIO?
iBio has a net margin of 3% compared to Green Thumb Industries's net margin of -4444.57%. Green Thumb Industries's return on equity of 3.66% beat iBio's return on equity of -148.3%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.45% $0.04 $2B IBIOiBio-- -$0.46 $22.3M -
What do Analysts Say About GTBIF or IBIO?
Green Thumb Industries has a consensus price target of --, signalling upside risk potential of 148.95%. On the other hand iBio has an analysts' consensus of -- which suggests that it could grow by 45.16%. Given that Green Thumb Industries has higher upside potential than iBio, analysts believe Green Thumb Industries is more attractive than iBio.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries0 0 0 IBIOiBio0 0 0 -
Is GTBIF or IBIO More Risky?
Green Thumb Industries has a beta of 1.574, which suggesting that the stock is 57.427% more volatile than S&P 500. In comparison iBio has a beta of -3.237, suggesting its less volatile than the S&P 500 by 423.713%.
-
Which is a Better Dividend Stock GTBIF or IBIO?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. iBio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. iBio pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or IBIO?
Green Thumb Industries quarterly revenues are $286.9M, which are larger than iBio quarterly revenues of $175K. Green Thumb Industries's net income of $8.6M is higher than iBio's net income of -$4M. Notably, Green Thumb Industries's price-to-earnings ratio is 29.37x while iBio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.70x versus -- for iBio. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.70x 29.37x $286.9M $8.6M IBIOiBio-- -- $175K -$4M
-
Which has Higher Returns GTBIF or NBY?
NovaBay Pharmaceuticals has a net margin of 3% compared to Green Thumb Industries's net margin of -49.65%. Green Thumb Industries's return on equity of 3.66% beat NovaBay Pharmaceuticals's return on equity of -461.38%.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.45% $0.04 $2B NBYNovaBay Pharmaceuticals65.26% -$0.60 $1.1M -
What do Analysts Say About GTBIF or NBY?
Green Thumb Industries has a consensus price target of --, signalling upside risk potential of 148.95%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 602.96%. Given that NovaBay Pharmaceuticals has higher upside potential than Green Thumb Industries, analysts believe NovaBay Pharmaceuticals is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries0 0 0 NBYNovaBay Pharmaceuticals0 0 0 -
Is GTBIF or NBY More Risky?
Green Thumb Industries has a beta of 1.574, which suggesting that the stock is 57.427% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.686, suggesting its less volatile than the S&P 500 by 31.383%.
-
Which is a Better Dividend Stock GTBIF or NBY?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or NBY?
Green Thumb Industries quarterly revenues are $286.9M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Green Thumb Industries's net income of $8.6M is higher than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Green Thumb Industries's price-to-earnings ratio is 29.37x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.70x versus 0.06x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.70x 29.37x $286.9M $8.6M NBYNovaBay Pharmaceuticals0.06x -- $2.4M -$1.2M
-
Which has Higher Returns GTBIF or OGEN?
Oragenics has a net margin of 3% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 3.66% beat Oragenics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.45% $0.04 $2B OGENOragenics-- -$0.38 -- -
What do Analysts Say About GTBIF or OGEN?
Green Thumb Industries has a consensus price target of --, signalling upside risk potential of 148.95%. On the other hand Oragenics has an analysts' consensus of -- which suggests that it could grow by 25237.83%. Given that Oragenics has higher upside potential than Green Thumb Industries, analysts believe Oragenics is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries0 0 0 OGENOragenics0 0 0 -
Is GTBIF or OGEN More Risky?
Green Thumb Industries has a beta of 1.574, which suggesting that the stock is 57.427% more volatile than S&P 500. In comparison Oragenics has a beta of 0.434, suggesting its less volatile than the S&P 500 by 56.551%.
-
Which is a Better Dividend Stock GTBIF or OGEN?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Oragenics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or OGEN?
Green Thumb Industries quarterly revenues are $286.9M, which are larger than Oragenics quarterly revenues of --. Green Thumb Industries's net income of $8.6M is higher than Oragenics's net income of -$2.5M. Notably, Green Thumb Industries's price-to-earnings ratio is 29.37x while Oragenics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.70x versus 1.40x for Oragenics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.70x 29.37x $286.9M $8.6M OGENOragenics1.40x -- -- -$2.5M
-
Which has Higher Returns GTBIF or PTN?
Palatin Technologies has a net margin of 3% compared to Green Thumb Industries's net margin of -2357.27%. Green Thumb Industries's return on equity of 3.66% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.45% $0.04 $2B PTNPalatin Technologies-- -$0.39 -$111.5K -
What do Analysts Say About GTBIF or PTN?
Green Thumb Industries has a consensus price target of --, signalling upside risk potential of 148.95%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 1656.38%. Given that Palatin Technologies has higher upside potential than Green Thumb Industries, analysts believe Palatin Technologies is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries0 0 0 PTNPalatin Technologies0 0 0 -
Is GTBIF or PTN More Risky?
Green Thumb Industries has a beta of 1.574, which suggesting that the stock is 57.427% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.901, suggesting its less volatile than the S&P 500 by 9.9%.
-
Which is a Better Dividend Stock GTBIF or PTN?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or PTN?
Green Thumb Industries quarterly revenues are $286.9M, which are larger than Palatin Technologies quarterly revenues of $350K. Green Thumb Industries's net income of $8.6M is higher than Palatin Technologies's net income of -$7.8M. Notably, Green Thumb Industries's price-to-earnings ratio is 29.37x while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.70x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.70x 29.37x $286.9M $8.6M PTNPalatin Technologies-- -- $350K -$7.8M
-
Which has Higher Returns GTBIF or TOVX?
Theriva Biologics has a net margin of 3% compared to Green Thumb Industries's net margin of --. Green Thumb Industries's return on equity of 3.66% beat Theriva Biologics's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital GTBIFGreen Thumb Industries51.45% $0.04 $2B TOVXTheriva Biologics-- -$6.81 -- -
What do Analysts Say About GTBIF or TOVX?
Green Thumb Industries has a consensus price target of --, signalling upside risk potential of 148.95%. On the other hand Theriva Biologics has an analysts' consensus of $100.00 which suggests that it could grow by 7838.6%. Given that Theriva Biologics has higher upside potential than Green Thumb Industries, analysts believe Theriva Biologics is more attractive than Green Thumb Industries.
Company Buy Ratings Hold Ratings Sell Ratings GTBIFGreen Thumb Industries0 0 0 TOVXTheriva Biologics1 0 0 -
Is GTBIF or TOVX More Risky?
Green Thumb Industries has a beta of 1.574, which suggesting that the stock is 57.427% more volatile than S&P 500. In comparison Theriva Biologics has a beta of 1.329, suggesting its more volatile than the S&P 500 by 32.874%.
-
Which is a Better Dividend Stock GTBIF or TOVX?
Green Thumb Industries has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Green Thumb Industries pays -- of its earnings as a dividend. Theriva Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios GTBIF or TOVX?
Green Thumb Industries quarterly revenues are $286.9M, which are larger than Theriva Biologics quarterly revenues of --. Green Thumb Industries's net income of $8.6M is higher than Theriva Biologics's net income of -$7.7M. Notably, Green Thumb Industries's price-to-earnings ratio is 29.37x while Theriva Biologics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Green Thumb Industries is 1.70x versus 0.90x for Theriva Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income GTBIFGreen Thumb Industries1.70x 29.37x $286.9M $8.6M TOVXTheriva Biologics0.90x -- -- -$7.7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 21
Quantum [QMCO] is up 26.28% over the past day.
Sell
46
NUKK alert for Dec 21
Nukkleus [NUKK] is down 22.94% over the past day.
Sell
1
IIPR alert for Dec 21
Innovative Industrial Properties [IIPR] is down 22.7% over the past day.
